NCT06805305 2026-04-22
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
Clinical Trials
19 trialsNCT07061964 2026-04-22
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02792582 2026-04-17
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06980038 2026-04-16
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07288112 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Diakonos Oncology Corporation
Phase 1/2 Recruiting
NCT03775265 2026-04-13
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04164082 2026-04-13
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT07000084 2026-04-07
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06914479 2026-03-11
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT06470282 2026-02-18
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
Phase 1/2 Recruiting
NCT05521698 2026-02-17
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Not yet recruiting
NCT04221503 2026-01-08
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT02621151 2025-10-07
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NYU Langone Health
Phase 2 Active not recruiting
NCT06338657 2025-09-16
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
University of Southern California
Phase 1 Terminated
NCT06629233 2025-08-29
Tn-Miner
University Ghent
Phase NA Enrolling by invitation
NCT06537154 2025-07-30
NEO-BLAST
University of British Columbia
Phase 2/3 Recruiting
NCT07067749 2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3 Recruiting